Semaglutide Cost Guide 2025: Brand vs Compounded Pricing

Brand-Name Semaglutide Pricing: Wegovy and Ozempic

Brand-name semaglutide is marketed under two primary trade names: Wegovy (approved for chronic weight management) and Ozempic (approved for type 2 diabetes). Both contain the same active ingredient, semaglutide, manufactured by Novo Nordisk, but they are priced differently and follow different insurance pathways.

Wegovy carries a wholesale acquisition cost (WAC) of approximately $1,349-$1,430 per month, making it one of the more expensive chronic medications on the market. This price reflects the full list price before any discounts, rebates, or insurance negotiations. The actual amount a patient pays depends entirely on their insurance coverage, pharmacy benefit structure, and any applicable manufacturer savings programs.

Ozempic, while containing the same molecule, is priced at $968-$1,023 per month at list price. The lower price reflects its diabetes indication and the competitive dynamics of the diabetes drug market. Some patients and providers have historically used Ozempic off-label for weight management due to its lower cost, though insurance coverage for off-label use is inconsistent and Novo Nordisk has actively discouraged this practice.

It is important to understand that list prices are not what most insured patients pay. After insurance negotiation, manufacturer rebates, and pharmacy benefit manager (PBM) processing, the actual out-of-pocket cost for commercially insured patients can range from $0 to several hundred dollars per month, depending on their specific plan design. For a comparison with tirzepatide pricing, see our cost-effectiveness comparison guide.

Insurance Coverage: The Complex Landscape

Insurance coverage for semaglutide is one of the most variable and rapidly evolving aspects of GLP-1 access. The coverage landscape differs dramatically based on the type of insurance, the indication for treatment, the specific plan design, and even the state in which the patient resides.

Commercial insurance plans (employer-sponsored and marketplace plans) provide the most variable coverage picture. Many plans now cover Ozempic for type 2 diabetes with standard copays, but coverage for Wegovy for weight management remains inconsistent. Some large employers have added obesity treatment coverage in recent years, recognizing the long-term cost savings of treating obesity as a chronic disease. However, even plans that nominally cover Wegovy often impose significant barriers: prior authorization requirements, step therapy (requiring failure of other weight loss methods first), BMI thresholds, and quantity limits.

Patients should verify their specific coverage by calling the member services number on their insurance card and asking specifically about coverage for the medication and indication their provider will prescribe. Coverage can change at any time, particularly during annual formulary updates, so verification should be repeated before each plan year. For patients without adequate coverage, see our guide on getting semaglutide without insurance.

Manufacturer Savings Programs and Patient Assistance

Novo Nordisk offers several programs designed to reduce out-of-pocket costs for eligible patients. Understanding these programs, their eligibility criteria, and their limitations is essential for patients seeking to minimize their costs while using brand-name semaglutide.

These programs have important limitations. Savings cards typically have annual maximum benefit limits, after which the patient becomes responsible for the full copay. Eligibility can change, and the programs may be modified or discontinued at Novo Nordisk's discretion. Government-insured patients (Medicare, Medicaid, Tricare, VA) are generally excluded from commercial savings card programs, though separate assistance programs may be available.

Third-party patient assistance organizations, such as the Patient Access Network Foundation and NeedyMeds, occasionally offer copay assistance for GLP-1 medications, though funding is limited and programs open and close frequently. Patients should check multiple resources and be prepared to apply quickly when funds become available.

Compounded Semaglutide: Pricing and Considerations

Compounded semaglutide has emerged as a significantly more affordable alternative to brand-name options for cash-pay patients. Compounding pharmacies can produce semaglutide preparations when there is a documented shortage of the brand-name product or when a patient requires a dosage form not commercially available. Pricing for compounded semaglutide is typically 70-85% lower than brand-name alternatives.

Monthly costs for compounded semaglutide programs generally range from $199 to $345, depending on the dose, the pharmacy, the included services (clinical oversight, provider consultations, supplies), and the billing structure (monthly vs. multi-month bundles). Some programs offer lower headline prices but charge separately for consultations, supplies, or shipping, making the true monthly cost higher than advertised.

When evaluating compounded semaglutide programs, patients should consider several factors beyond price. Verify that the compounding pharmacy holds current FDA registration and complies with either Section 503A (patient-specific prescriptions) or Section 503B (outsourcing facility) requirements. Confirm that the program includes genuine clinical oversight with licensed providers who review medical history, monitor progress, and adjust dosing. Be wary of programs that advertise unusually low prices, require no clinical evaluation, or ship medication without a valid prescription. For a detailed comparison with brand options, see our article on compounded vs brand-name semaglutide.

Monthly Cost Breakdown by Dose

Semaglutide treatment follows a dose-escalation schedule, starting at a low dose and increasing over 16-20 weeks to the target maintenance dose. Understanding the cost at each dose level helps patients plan their treatment budget and anticipate expenses over the full course of therapy.

For brand-name Wegovy, the price remains consistent across all dose levels because each pen is a single-dose device priced at the same rate regardless of the semaglutide content. Whether a patient is on the 0.25 mg starting dose or the 2.4 mg maintenance dose, the monthly cost to the pharmacy is the same. This means patients pay the same copay or cash price throughout the entire dose-escalation and maintenance phases.

Compounded semaglutide programs may price differently. Some charge a flat rate regardless of dose, while others have tiered pricing that increases as the dose increases, reflecting the higher cost of active ingredient required for larger doses. Monthly costs for compounded programs typically range from $199-$249 at lower doses (0.25-0.5 mg weekly) to $279-$345 at maintenance doses (1.7-2.4 mg weekly). Understanding the full dose-escalation cost trajectory helps patients avoid surprises and plan for the total investment over the first several months of treatment.

The True Cost of Treatment: Beyond the Monthly Price

When comparing semaglutide options, the monthly medication price is only one component of the total cost of care. A comprehensive cost analysis should include provider consultations, lab work, supplies (needles, alcohol swabs), shipping costs, and any program fees charged by telehealth platforms or weight management clinics.

Brand-name semaglutide through a traditional healthcare provider includes office visit copays (typically $25-75 per visit), lab work for monitoring (often covered by insurance), and pharmacy copays or coinsurance for the medication itself. The total monthly cost for an insured patient with good coverage might be $50-200, while an uninsured patient faces the full list price of $1,000+ plus provider fees.

Telehealth-based compounded programs typically bundle medication, clinical oversight, and supplies into a single monthly fee, which simplifies cost comparison but can obscure the value breakdown. Some programs include unlimited messaging with providers, regular check-ins, nutritional guidance, and dosing adjustments in their monthly fee, while others charge additional fees for anything beyond basic medication dispensing. The most comprehensive programs offer value that extends well beyond the medication itself.

Long-term cost considerations are also important. Semaglutide is currently understood to require ongoing treatment for sustained weight maintenance. A patient planning for 12-24 months of treatment at $300 per month is looking at a total investment of $3,600-$7,200. When weighed against the healthcare costs associated with untreated obesity, including increased risk of diabetes, cardiovascular disease, joint replacement, and other conditions, GLP-1 therapy has been shown to be cost-effective in multiple health economic analyses. For broader cost comparisons across GLP-1 options, visit our weight loss injection costs comparison.

Cost-Saving Strategies for Semaglutide Patients

Regardless of which semaglutide option a patient chooses, there are strategies that can reduce costs without compromising the quality or safety of treatment. These approaches are not mutually exclusive and can be combined for maximum savings.

Patients should approach cost discussions proactively with their healthcare providers. Many providers have experience navigating insurance barriers and can offer prior authorization support, appeal letters, and alternative treatment pathways that improve affordability. For the latest on affordable access, explore our detailed semaglutide cost breakdown.

Sources

1. Novo Nordisk. Wegovy (semaglutide) Prescribing Information and Pricing. 2024.
2. Novo Nordisk. Ozempic (semaglutide) Prescribing Information and Pricing. 2024.
3. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Requirements. 2024.
4. Institute for Clinical and Economic Review (ICER). Medications for Obesity Management: Effectiveness and Value. 2022.
5. FDA. Compounding and the FDA: Questions and Answers. 2023.
6. Amaro A, et al. Cost-effectiveness of semaglutide for weight management. Pharmacoeconomics. 2024;42(3):289-305.